Headline: Eli Lilly & Co. Posts Q4 25 Earnings, Shares Jump on Strong Pharma Performance - LLY

[Para 1: The Lead] Eli Lilly & Co. (LLY) reported a 12% increase in Q4 25 earnings per share to $2.35, exceeding Wall Street estimates by 15%, according to the company's earnings call at 10:00 AM ET. The pharmaceutical giant's strong performance in its core products, including diabetes and oncology drugs, fueled the earnings boost. [Para 2-3: Supporting details & Context] Revenue for the quarter climbed 7% to $6.2 billion, driven by robust sales in its key franchises. Shares of LLY surged 7% in after-hours trading following the release. The company also announced a 10% increase in its dividend, reflecting confidence in its growth prospects. Eli Lilly's forward guidance indicates continued momentum in 2026, with a focus on innovation and market share expansion.